Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig in High-risk Asthma
NCT06676319Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Lunsekimig with Placebo (2 arms). Primary endpoint: Annualized rate of asthma exacerbation events at 52 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06676319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676319.